简体
  • 简体中文
  • 繁体中文

热门资讯> 正文

Dyadic Applied Biomosolves宣布与Opes Diagnostics达成商业协议,支持Dyadic用于无血清细胞培养液应用的重组人转铁蛋白、牛转铁蛋白、人GF和牛GF产品的商业推出

2025-12-15 20:26

  • Under the agreement, Opes will leverage its existing commercial relationships and market experience to identify and engage potential customers primarily in Europe, Israel, and Asia to accelerate market entry for Dyadic's recombinant protein portfolio in cell culture media and related applications, while Dyadic retains the ability to sell directly and to work with additional partners globally.
  • The collaboration is intended to accelerate the penetration of Dyadic's recombinant protein products produced using its microbial expression platforms in industries including research, diagnostics, cultured meat and life sciences biomanufacturing that require reliable, scalable, and cost-effective sources of growth factors and functional proteins.   Opes has already sampled multiple customers utilizing serum free cell culture media in life sciences, food and nutrition applications.

风险及免责提示:以上内容仅代表作者的个人立场和观点,不代表华盛的任何立场,华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前,应结合自身情况,考虑投资产品的风险。必要时,请咨询专业投资顾问的意见。华盛不提供任何投资建议,对此亦不做任何承诺和保证。